Want to see TXMD full AI Analyst Report?
TXMD Stock Chart & Stats
$1.68
-$0.07(-6.14%)
At close: 4:00 PM EST
$1.68
-$0.07(-6.14%)
Day’s Range― - ―
52-Week Range$0.99 - $2.95
Previous CloseN/A
Volume92.69K
Average Volume (3M)310.58K
Market Cap
$22.80M
Enterprise Value$20.92
Total Cash (Recent Filing)$8.42M
Total Debt (Recent Filing)$5.83M
Price to Earnings (P/E)126.0
Beta1.08
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding11,574,362
10 Day Avg. Volume897,126
30 Day Avg. Volume310,579
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)0.70
Price to Sales (P/S)6.24
P/FCF Ratio7.78
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.17
Revenue Forecast (FY)$9.30M
Bulls Say, Bears Say
Bulls Say
Improving Cash GenerationOperating and free cash flow turned positive and are growing, reflecting materially improved cash discipline. Durable cash generation reduces reliance on external funding, supports working capital and strategic choices, and provides runway to pursue partnerships or M&A over months.
Low Leverage / Stable Balance SheetA modest debt-to-equity ratio and positive equity indicate low solvency risk and financial flexibility. This durable capital structure allows management to fund operations, absorb shocks, or pursue strategic transactions without immediate refinancing pressure over the medium term.
High Gross Margins & Diversifying License RevenueStrong gross margins imply attractive product economics that can scale profitably if top-line stabilizes. Growing license revenue diversifies income and the quarter's shift to positive net income shows improving earnings mix, supporting longer-term margin recovery if revenues stabilize.
Bears Say
Declining Revenue / Limited ScaleA 13% TTM revenue decline indicates weakening demand or commercial traction, constraining economies of scale. Persistent top-line erosion undermines sustainable margin expansion and makes it harder to cover fixed costs, threatening cash generation durability absent a clear revenue turnaround.
Operating Profitability Still NegativeDespite net income turning slightly positive, core operating and EBITDA margins remain negative, signaling the operating business hasn't normalized. Reliance on non‑operating items or one-off gains to reach net profit increases execution risk over the medium term.
Strategic-Alternatives UncertaintyActive evaluation of strategic alternatives (M&A, asset sales, monetizing royalties) creates structural uncertainty. Outcomes could materially change capital allocation and operations; lack of timetable reduces predictability and may delay investments or distract management from execution.
TherapeuticsMD News
TXMD FAQ
What was TherapeuticsMD’s price range in the past 12 months?
TherapeuticsMD lowest stock price was $0.99 and its highest was $2.95 in the past 12 months.
What is TherapeuticsMD’s market cap?
TherapeuticsMD’s market cap is $22.80M.
When is TherapeuticsMD’s upcoming earnings report date?
TherapeuticsMD’s upcoming earnings report date is Aug 17, 2026 which is in 32 days.
How were TherapeuticsMD’s earnings last quarter?
TherapeuticsMD released its earnings results on May 12, 2026. The company reported $0.008 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is TherapeuticsMD overvalued?
According to Wall Street analysts TherapeuticsMD’s price is currently Overvalued.
Does TherapeuticsMD pay dividends?
TherapeuticsMD does not currently pay dividends.
What is TherapeuticsMD’s EPS estimate?
TherapeuticsMD’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TherapeuticsMD have?
TherapeuticsMD has 11,574,362 shares outstanding.
What happened to TherapeuticsMD’s price movement after its last earnings report?
TherapeuticsMD reported an EPS of $0.008 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.59%.
Which hedge fund is a major shareholder of TherapeuticsMD?
Currently, no hedge funds are holding shares in TXMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
TherapeuticsMD
TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17ß-estradiol and progesterone, used to alleviate moderate to severe vasomotor symptoms; and ANNOVERA, an innovative vaginal ring designed for contraception. In its developmental pipeline, TherapeuticsMD is advancing several preclinical candidates: TX-005HR, a transdermal cream containing only progesterone; TX-006HR, another transdermal cream formulated with both estradiol and progesterone; TX-007HR and TX-008HR, both experimental transdermal patches; and TX-009HR, an oral formulation of progesterone and estradiol. Beyond its core pharmaceutical offerings, the company produces and distributes both branded and generic prescription prenatal vitamins, notably under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 labels. Its prescription medications and prenatal vitamin lines reach consumers through established channels, including wholesale and retail pharmacy distributors. Established in 2008, TherapeuticsMD, Inc. maintains its corporate headquarters in Boca Raton, Florida.
Technical Analysis
Ownership Overview
1.56% Insiders
4.11% Mutual Funds
24.44% Other Institutional Investors
66.74% Public Companies and
Individual Investors